Business Description
I-MAB
ISIN : US44975P1030
Share Class Description:
IMAB: ADRDescription
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 37.91 | |||||
| Equity-to-Asset | 0.7 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -3.08 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -6.3 | |||||
| 3-Year EPS without NRI Growth Rate | -4.7 | |||||
| 3-Year FCF Growth Rate | 2.7 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.78 | |||||
| 9-Day RSI | 46.34 | |||||
| 14-Day RSI | 48.51 | |||||
| 6-1 Month Momentum % | 52.03 | |||||
| 12-1 Month Momentum % | -44.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.64 | |||||
| Quick Ratio | 4.64 | |||||
| Cash Ratio | 4.44 | |||||
| Days Inventory | 399.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.8 | |||||
| Shareholder Yield % | 3.98 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 112.29 | |||||
| Operating Margin % | 697.92 | |||||
| Net Margin % | 870.2 | |||||
| FCF Margin % | 461.29 | |||||
| ROE % | -70.07 | |||||
| ROA % | -52.31 | |||||
| ROIC % | -304.63 | |||||
| ROC (Joel Greenblatt) % | -1690.99 | |||||
| ROCE % | -62.18 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.43 | |||||
| Price-to-Tangible-Book | 0.49 | |||||
| EV-to-EBIT | 0.8 | |||||
| EV-to-Forward-EBIT | -0.01 | |||||
| EV-to-EBITDA | 0.81 | |||||
| EV-to-Forward-EBITDA | -0.01 | |||||
| EV-to-Revenue | 6.99 | |||||
| EV-to-Forward-Revenue | 0.23 | |||||
| EV-to-FCF | 1.52 | |||||
| Price-to-Net-Current-Asset-Value | 0.53 | |||||
| Price-to-Net-Cash | 0.57 | |||||
| Earnings Yield (Greenblatt) % | 125 | |||||
| FCF Yield % | -115.83 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IMAB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
I-MAB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | -36.474 | ||
| EPS (TTM) ($) | -3.828 | ||
| Beta | 1.21 | ||
| Volatility % | 54.92 | ||
| 14-Day RSI | 48.51 | ||
| 14-Day ATR ($) | 0.074886 | ||
| 20-Day SMA ($) | 1.8185 | ||
| 12-1 Month Momentum % | -44.18 | ||
| 52-Week Range ($) | 1.16 - 3.45 | ||
| Shares Outstanding (Mil) | 80.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
I-MAB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
I-MAB Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
I-MAB Frequently Asked Questions
What is I-MAB(IMAB)'s stock price today?
The current price of IMAB is $1.80. The 52 week high of IMAB is $3.45 and 52 week low is $1.16.
When is next earnings date of I-MAB(IMAB)?
The next earnings date of I-MAB(IMAB) is 2024-08-16 Est..
Does I-MAB(IMAB) pay dividends? If so, how much?
I-MAB(IMAB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers